“I am pleased to announce Anders Vadsholt as CFO for Camurus, succeeding Jon Garay Alonso, who will remain with the company until August to ensure a smooth transition,” says Fredrik Tiberg, Camurus’ President and CEO. “I look forward to welcoming Anders to our executive management team and working together to continue our successful development and to grow and diversify our business. Also, I want to thank Jon for his significant contributions during his tenure as Camurus’ CFO and wish him the best in the future.”

Anders Vadsholt

Anders Vadsholt has financial and M&A expertise from executive roles in the biotech and pharmaceutical sector, including serving as CFO for the publicly listed companies Orphazyme and Topotarget. Additionally, he has worked as a Partner at Bankinvest Biomedical Ventures (Private Equity) and in corporate finance at Carnegie.

“Camurus’ clear focus on improving the lives of people with severe and chronic diseases, combined with its integrated approach from research to commercialization, makes it a uniquely purpose-driven and scalable business”, says Anders Vadsholt. “I am excited to contribute to the company’s continued growth and long-term value creation.”